A 58-year-old man with type 2 diabetes is on glibenclamide but develops recurrent hypoglycemic episodes despite regular meals. His HbA1c is 6.2%. Which pharmacologic feature of glibenclamide best explains this problem, and how does switching to a DPP-4 inhibitor address it?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.